News
A new study will evaluate the safety and efficacy of universal allogeneic anti-CD19/BCMA CAR T-cells in relapsed or refractory autoimmune diseases including antineutrophil cytoplasmic antibody ...
Estrella Immunopharma, Inc. (NASDAQ: ESLA) ("Estrella" or the "Company"), a clinical stage biopharmaceutical company ...
1d
TipRanks on MSNEstrella Immunopharma Raises $3.35M in Private PlacementEstrella Immunopharma ( ($ESLA) ) has shared an announcement. On May 30, 2025, Estrella Immunopharma entered into a securities purchase agreement ...
Researchers at Friedrich-Alexander-Universität Erlangen-Nürnberg have identified a previously undocumented, organ-specific ...
B-cell acute lymphoblastic leukemia (B-ALL) is the most common cancer in children, accounting for around 85% of pediatric ...
The autologous immunotherapy consists of the patient’s own T cells engineered to express a chimeric antigen receptor that ...
HemOnc Today hosted its fourth Disruptive Innovators Awards ceremony, crowning nine new winners at ASCO Annual Meeting. Co-hosted by Shikha Jain, MD, FACP, founder of Women in Medicine, and Ed S. Kim, ...
The spring meeting of the Irish Society for Rheumatology brought together experts from across Ireland and the UK to highlight ...
The IRAK4 long isoform as widely upregulated in non-splicesome mutated acute myeloid leukemia and as altered by hypomethylating agent therapy. This is an ASCO Meeting Abstract from the 2025 ASCO ...
Clinical characteristics and treatment outcomes of hepatosplenic T-cell lymphoma: Mayo Clinic experience. Frontline brentuximab vedotin (BV) and CHP in patients (pts) with peripheral T-cell lymphoma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results